GLUCOSE CONTROL DURING CORONAVIRUS DISEASE IN TYPE 1 DIABETES PATIENT ON SENSOR AUGMENTED PUMP
Journal
Diabetes technology & therapeutics
Date Issued
2021-06
Author(s)
DOI
10.1089/dia.2021.2525.abstracts
Abstract
Introduction:Since the outbreak of novel coronavirus Sars-CoV-2 pandemic, much attention has focused on patients with diabetes due to increased risk of infection.
This increased risk of infection is due to hyperglycemia induced immune dysfunction (damage to the neutrophil function, depression of the antioxidant system, and humoral immunity), micro- and macro-angiopathies, and greater requirement of medical interventions in these patients.
Since it is well established that uncontrolled hyperglycemia impairs immune function in all forms of diabetes, it would be logical to presume that T1D, particularly if not well controlled, could have an increased risk of infection and intensifying
glycemic control could serve as a means of primary prevention.
We present the case of a patient with type 1 diabetes and mild clinical presentation of Sars-CoV-2 infection during June 2020, successfully managed with SAP (Sensor Augmented Pump Therapy, Medtronic Minimed Veo Enlite sensor). Case report: A 33 year old patient with history of type 1 diabetes for
the last 14 years and primary hypothyroidism for 8 years,
presented with fever, cough, muscle aches, headache and
new loss of smell. RT-PCR smear confirmed the presence
of a SARS-CoV-2. The last 8 years patient was on insulin
pump therapy with intermittent use of glucose sensor. Her
last A1c was 7.7% and she doesn’t have any diabetes
complications.
As it was a mild clinical presentation of COVID-19 (with
absence of viral pneumonia and hypoxia) she did not
require hospitalization and was able to manage her illness
at home.
Patient contacted our clinic and underwent online reeducation about “sick day rules”, upload of insulin pump
data using CareLink Therapy Management Personal
Software (Medtronic, Northridge, CA) and was advised to
insert glucose sensor. We made daily online follow up of
glucose profile and adjustments in insulin requirements.
Basal dose of insulin was adjusted using temporary basal
rate (70-80% of basal rate) which allowed stable glycemic
control with Avg BG 8.9 ± 3.4mmol/L, GMI-6,2% (43,9
mmol/mol) during 14 days following confirmation of SarsCoV-2 infection. Conclusion: SAP is helpful in monitoring glucose during viral infections allowing prompt action and prevention of further complications like DKA. In settings of COVID-19 pandemic, remote monitoring enables physicians and other health-care professionals to intervene timely in patients and improve clinical outcomes.
This increased risk of infection is due to hyperglycemia induced immune dysfunction (damage to the neutrophil function, depression of the antioxidant system, and humoral immunity), micro- and macro-angiopathies, and greater requirement of medical interventions in these patients.
Since it is well established that uncontrolled hyperglycemia impairs immune function in all forms of diabetes, it would be logical to presume that T1D, particularly if not well controlled, could have an increased risk of infection and intensifying
glycemic control could serve as a means of primary prevention.
We present the case of a patient with type 1 diabetes and mild clinical presentation of Sars-CoV-2 infection during June 2020, successfully managed with SAP (Sensor Augmented Pump Therapy, Medtronic Minimed Veo Enlite sensor). Case report: A 33 year old patient with history of type 1 diabetes for
the last 14 years and primary hypothyroidism for 8 years,
presented with fever, cough, muscle aches, headache and
new loss of smell. RT-PCR smear confirmed the presence
of a SARS-CoV-2. The last 8 years patient was on insulin
pump therapy with intermittent use of glucose sensor. Her
last A1c was 7.7% and she doesn’t have any diabetes
complications.
As it was a mild clinical presentation of COVID-19 (with
absence of viral pneumonia and hypoxia) she did not
require hospitalization and was able to manage her illness
at home.
Patient contacted our clinic and underwent online reeducation about “sick day rules”, upload of insulin pump
data using CareLink Therapy Management Personal
Software (Medtronic, Northridge, CA) and was advised to
insert glucose sensor. We made daily online follow up of
glucose profile and adjustments in insulin requirements.
Basal dose of insulin was adjusted using temporary basal
rate (70-80% of basal rate) which allowed stable glycemic
control with Avg BG 8.9 ± 3.4mmol/L, GMI-6,2% (43,9
mmol/mol) during 14 days following confirmation of SarsCoV-2 infection. Conclusion: SAP is helpful in monitoring glucose during viral infections allowing prompt action and prevention of further complications like DKA. In settings of COVID-19 pandemic, remote monitoring enables physicians and other health-care professionals to intervene timely in patients and improve clinical outcomes.
File(s)![Thumbnail Image]()
![Thumbnail Image]()
Loading...
Name
Inkedread2021.jpg
Size
115.92 KB
Format
JPEG
Checksum
(MD5):b8423525227ddd5300f26c4ad6b0e695
Loading...
Name
ATTD2021.png
Size
51.01 KB
Format
PNG
Checksum
(MD5):67dde828705a44abdad7063d4cff0b77